
Cardinal Health At-Home is owned by Cardinal Health, Inc. (NYSE: CAH), a publicly traded American healthcare company headquartered in Dublin, Ohio. The division operates as a wholly-owned brand within Cardinal Health's Other segment, delivering medical supplies, equipment, and pharmacy services directly to patients in the United States. Cardinal Health reported $222.6 billion in fiscal year 2025 revenue and continues expanding its at-home capabilities through acquisitions.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Cardinal Health At-Home | Cardinal Health | Brand division |
Cardinal Health launched its at-Home Solutions business in 2014 as part of a broader strategy to diversify beyond its core pharmaceutical distribution operations. The initial focus was providing durable medical equipment and disposable medical supplies to patients managing chronic conditions at home.
The division grew slowly in its early years. Cardinal Health was primarily known as a pharmaceutical wholesaler, and the at-home market was a small fraction of its total business. The company supplied products for diabetes management, wound care, urology, ostomy, and incontinence through partnerships with health plans and providers.
A turning point came in 2024 when Cardinal Health acquired Advanced Diabetes Supply (ADS), a direct-to-patient diabetes supply company. The ADS acquisition gave Cardinal Health a national platform for shipping continuous glucose monitors, insulin pump supplies, and testing strips directly to patients' homes. It also brought an established customer base and relationships with major insurance plans.
Following the ADS acquisition, Cardinal Health integrated the business into its at-Home Solutions distribution network. The company migrated all ADS volume onto its technology-enabled distribution platform. According to Cardinal Health, the integration was completed ahead of plan. The division onboarded nearly 500,000 new customers in the first year after closing the ADS deal.
In 2025, Cardinal Health launched the ContinuCare Pathway program. This is a digital referral system that connects partner pharmacies with at-Home Solutions for diabetes supply fulfillment. The program allows pharmacies to refer patients who need diabetes supplies directly to Cardinal Health's distribution network. Cardinal Health announced a key partnership with Publix Super Markets Inc. as part of this initiative.
The company also expanded through its Specialty Alliance platform. In November 2025, The Specialty Alliance completed the acquisition of Solaris Health, the country's largest urology management services organization (MSO) with over 750 providers. While Solaris Health operates under the Specialty Solutions segment rather than at-Home Solutions, it creates referral pathways for urology patients who may need home-based medical supplies.
In July 2026, Cardinal Health announced two more acquisitions to accelerate its at-Home Solutions growth. The company agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASDAQ: AHCO) and Strive Medical, a multi-specialty supply provider focused on urology. The combined transaction value is approximately $360 million in cash. Both deals are expected to close subject to regulatory approvals and customary closing conditions.
CEO Jason Hollar described these acquisitions as a natural extension of the at-Home Solutions growth strategy. They expand Cardinal Health's depth in diabetes management and urology, two therapeutic categories with significant home-care demand. The transactions are expected to be accretive to non-GAAP earnings per share within the first 12 months following close.
Rob Schlissberg, President of at-Home Solutions, stated that the operational achievements in fiscal year 2026 position Cardinal Health to continue building what he called the country's leading platform for home-based care. The company is pursuing both organic growth and acquisitions to expand its capabilities.
Cardinal Health's at-Home Solutions business is still small relative to the company's Pharmaceutical and Specialty Solutions segment, which generated $687 million in segment profit alone in the second quarter of fiscal year 2026. But the Other segment's 31% revenue growth rate significantly outpaces the core pharmaceutical distribution business, making at-Home Solutions a strategic priority for future expansion.
Is Cardinal Health a subsidiary of another company?
No. Cardinal Health is an independent, publicly traded corporation with no parent company. The company operates independently with its own management structure and board of directors, though it has grown through numerous acquisitions throughout its history.
Is Cardinal Health publicly traded?
Yes. Cardinal Health is publicly traded on the New York Stock Exchange under the ticker symbol CAH. The company has been publicly traded since its IPO in 1983.
When was Cardinal Health founded?
Cardinal Health was founded in 1971 by Robert Walter as a food distributor in Columbus, Ohio. The company entered the pharmaceutical distribution business in 1979, marking the beginning of its transformation into a healthcare services company.
Who founded Cardinal Health?
Cardinal Health was founded by Robert Walter, who started the company as a small food distributor in Columbus, Ohio. Walter's vision and leadership guided the company's transformation into one of the largest healthcare distribution companies in the world.
What is Cardinal Health's annual revenue?
Cardinal Health reported FY2025 revenue of $222.6 billion (fiscal year ended June 30, 2025), a 2 percent decrease from FY2024 due to the OptumRx contract expiration. Excluding this impact, revenue increased 18 percent. Through the first three quarters of FY2026, revenue was $190.6 billion, up 17 percent year-over-year.
Who is Cardinal Health's CEO?
Jason Hollar serves as CEO of Cardinal Health. Hollar described FY2025 as a "transformative year" and has led the company's strategic shift toward specialty healthcare services through The Specialty Alliance MSO platform.
What is The Specialty Alliance?
The Specialty Alliance is Cardinal Health's multi-specialty management services organization (MSO) platform, providing administrative and management services to physician practices. It includes GI Alliance (gastroenterology with 900+ physicians), Urology Alliance (urology with 750+ providers through Solaris Health and other acquisitions), and Navista (oncology with 50+ practice sites). Cardinal Health owns approximately 75 percent of The Specialty Alliance following the Solaris Health acquisition.
What is Cardinal Health's opioid settlement obligation?
Cardinal Health has $4.9 billion accrued as of June 30, 2025 for opioid litigation settlements, including the National Opioid Settlement Agreement (NOSA). The company made payments of $798 million in FY2025 and a fifth annual NOSA payment of $366 million in July 2025. The majority of remaining payments are expected through 2038.
Cardinal Health publishes an annual ESG report covering environmental impact, social responsibility, and governance practices. The company has set targets for reducing greenhouse gas emissions and has invested in sustainable packaging for its medical product lines.
However, the at-Home Solutions division does not have independently verified sustainability certifications from recognized third-party organizations. The standard certifications tracked in consumer goods, such as cruelty-free, vegan, B Corp, or organic certifications, do not apply to a B2B medical supply distribution business.
Cardinal Health's ethics practices include a code of conduct for employees and suppliers, compliance training programs, and a whistleblower hotline. The company is subject to FDA regulations governing medical device distribution and must maintain compliance with the Drug Supply Chain Security Act for pharmaceutical distribution.
In terms of social impact, Cardinal Health's at-Home Solutions improves healthcare access for patients with limited mobility or those living in rural areas. The direct-to-patient model reduces barriers to obtaining essential medical supplies for chronic condition management.
Cardinal Health as a parent company has received recognition for its workplace culture and business performance. The company has been named to the Forbes list of America's Best Employers and has received recognition from the Human Rights Campaign for LGBTQ+ workplace equality.
The at-Home Solutions division specifically has not been the subject of major industry awards as of August 2026. The division's growth strategy and acquisitions have been noted in healthcare industry publications, but formal awards at the division level are limited.
Cardinal Health has faced regulatory scrutiny at the corporate level that indirectly affects its at-Home Solutions business. In April 2024, the FDA issued a warning letter to Cardinal Health's facility in Waukegan, Illinois, related to quality system violations for medical device distribution. The letter cited failures in complaint handling and corrective action procedures. Cardinal Health responded with a remediation plan and has stated that it is working to address all FDA observations.
The company has also faced litigation related to its role in the opioid epidemic. Cardinal Health was one of several pharmaceutical distributors that settled with states, local governments, and tribal nations for a combined total exceeding $20 billion across the industry. Cardinal Health's specific settlement obligations extend over 18 years and have been incorporated into the company's financial reporting.
The at-Home Solutions division itself has not been the subject of specific recalls or controversies. However, the July 2026 acquisition of AdaptHealth's diabetes business brings potential exposure to AdaptHealth's historical regulatory issues, including a 2023 data breach that affected over 12,000 patients. Cardinal Health will need to integrate AdaptHealth's diabetes operations while ensuring compliance with HIPAA and data security standards.
No direct competitors found in the same category. This could be because Cardinal Health At-Homeoperates in a unique market segment or we're still building our competitor database.
Looking for brands with different ownership structures? These similar brands are not owned by Cardinal Health, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Cardinal Health At-Home which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Cardinal Health At-Home which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Cardinal Health At-Home which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
Bausch + Lomb operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.